Zobrazeno 1 - 7
of 7
pro vyhledávání: '"J S, Hostetler"'
Publikováno v:
Antimicrobial Agents and Chemotherapy. 37:2224-2227
Pharmacologic studies of itraconazole (IZ), a triazole antifungal, indicated unexplained differences between bioassay and chromatographic determinations and large variations in steady-state blood concentrations. We show that concentrations of a hydro
Publikováno v:
Clinical and Experimental Immunology. 94:11-16
SUMMARYParacoccidioidomycosis is characterized by depressed cellular but enhanced humoral immune responses, which suggests a Th2 type of response to infection. We investigated possible therapeutic roles for anti-IL-4, interferon-gamma (IFN-γ) and/or
Publikováno v:
Antimicrobial Agents and Chemotherapy. 36:477-480
Concentrations of oral azoles in serum were compared in a single-dose pharmacologic study in mice. When hydroxypropyl-beta-cyclodextrin was used as a carrier and compared with a standard carrier, polyethylene glycol, drug concentrations determined by
Autor:
P K, Sharkey-Mathis, C A, Kauffman, J R, Graybill, D A, Stevens, J S, Hostetler, G, Cloud, W E, Dismukes
Publikováno v:
The American journal of medicine. 95(3)
To describe the clinical presentation and outcomes of treatment with itraconazole in patients with sporotrichosis.A culture for Sporothrix schenckii or compatible histopathology was required for inclusion in the study. Patients with both cutaneous an
Publikováno v:
Antimicrobial agents and chemotherapy. 36(12)
The efficacy and safety of amphotericin B colloidal dispersion (ABCD) were compared with those of amphotericin B deoxycholate suspension (ABDS) (Fungizone) in a murine model of disseminated cryptococcosis. Mice were treated intravenously with either
Publikováno v:
Chemotherapy. 38
Itraconazole has emerged as an important new oral agent in the treatment of systemic fungal infections. This paper summarizes the data available on its use in aspergillosis, cryptococcosis and histoplasmosis, compiled in the United States with partic
Autor:
J S, Hostetler, D A, Stevens
Publikováno v:
Medizinische Klinik (Munich, Germany : 1983). 86
Itraconazole has emerged as an important new oral agent in the treatment of systemic fungal infections. We report a summary of available data on its use in aspergillosis, cryptococcosis and histoplasmosis compiled in the United States with particular